文献速递毛发、甲与色素性疾病

Deuruxolitinib治疗成人斑秃的THRIVE-AA2 III期随机对照试验

Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial.
PubMed 文献 · J Am Acad Dermatol · 2025-11-27

THRIVE-AA2是一项随机、双盲、安慰剂对照、多中心III期试验,纳入517例SALT评分≥50且病程≥6个月的成人重度斑秃患者,评估口服选择性JAK1/2抑制剂deuruxolitinib的疗效与安全性。第24周时,deuruxolitinib 8 mg BID组33.0%、12 mg BID组38.3%患者达到SALT20,安慰剂组仅0.8%(两剂量组对安慰剂P<.0001)。药物耐受性良好,多数治疗相关不良事件为轻中度。

要点

  • Deuruxolitinib 8 mg和12 mg BID均显著提高第24周SALT20达标率,优于安慰剂。
  • 12 mg BID组SALT20达标率38.3%,8 mg BID组33.0%,安慰剂组0.8%。
  • 药物耐受性良好,多数治疗相关不良事件为轻中度。

核心结论

  • 疗效与安全性分析支持deuruxolitinib作为成人斑秃的治疗选择。

研究设计与样本

  • 随机、双盲、安慰剂对照、多中心III期试验(NCT04797650)。
  • 纳入18至65岁、SALT评分≥50且筛选时斑秃病程≥6个月的患者。
  • 患者按1:2:1随机分配至deuruxolitinib 12 mg每日两次、8 mg每日两次或安慰剂组。
  • 共517例患者随机化,515例接受至少一剂研究药物。

主要发现

  • 第24周达到SALT20的患者比例:deuruxolitinib 8 mg BID组33.0%,12 mg BID组38.3%,安慰剂组0.8%。
  • 两个deuruxolitinib剂量组对安慰剂的P值均<.0001。
  • Deuruxolitinib耐受性良好,多数研究药物相关治疗中出现的不良事件为轻或中度。

临床怎么用

  • 对于SALT评分≥50的成人重度斑秃患者,可考虑使用deuruxolitinib 8 mg或12 mg每日两次治疗。

局限性

  • 未评估长期疗效和安全性或治疗反应的持久性,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alopecia areata (AA) is an autoimmune disease resulting in patchy or complete hair loss. OBJECTIVE: We report safety and efficacy results of deuruxolitinib, a selective Janus kinase 1/2 inhibitor, in adults with severe chronic AA. METHODS: We conducted a randomized, double-blind, placebo-controlled, multicenter trial (NCT04797650). Patients aged 18 to 65 years with a Severity of Alopecia Tool (SALT) score ≥50 and an AA episode lasting ≥6 months at screening were randomized 1:2:1 to deuruxolitinib 12 mg twice daily (BID), 8 mg BID, or placebo between June 10 and December 13, 2021. The primary endpoint was the percentage of patients achieving a SALT score ≤20 (SALT20) at Week 24. RESULTS: Of 517 patients randomized, 515 received ≥1 dose of study drug. At Week 24, 33.0%, 38.3%, and 0.8% of patients receiving deuruxolitinib 8 mg BID, 12 mg BID, and placebo, respectively, achieved SALT20 (P < .0001 vs placebo for both doses). Deuruxolitinib was well tolerated, and most study drug-related treatment-emergent adverse events were mild or moderate in severity. LIMITATIONS: Long-term efficacy and safety or durability of treatment response were not assessed; further study is required. CONCLUSION: Efficacy and safety analyses support deuruxolitinib as a treatment option in adults with AA.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Tsianakas A, Passeron T, Magnolo N, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial. J Am Acad Dermatol. 2025. PMID: 41317911. doi:10.1016/j.jaad.2025.11.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。